FMS stands for Fibromyalgia Syndrome, a chronic condition that amplifies the way your nervous system processes pain signals. It affects up to 5% of the global population and causes widespread pain, deep fatigue, and a range of other symptoms that can disrupt daily life. Unlike conditions such as arthritis, FMS doesn’t involve inflammation or damage to the tissues that hurt.
How FMS Affects the Nervous System
Fibromyalgia Syndrome is fundamentally a pain-processing problem. In a healthy nervous system, pain signals travel from the body to the brain and get filtered along the way. In people with FMS, that filtering system breaks down. The brain turns up the volume on pain signals and turns down its own built-in pain suppression, creating a state called central sensitization where normal sensory input gets interpreted as painful.
Several specific chemical imbalances drive this process. Levels of substance P, a chemical that transmits pain signals, run up to three times higher than normal in the spinal fluid of people with FMS. Glutamate, another excitatory brain chemical, is also elevated. At the same time, serotonin and norepinephrine, which normally help dampen pain as it travels down the spinal cord, are lower than they should be. The result is a nervous system stuck in a heightened state: pain signals get amplified, and the body’s natural ability to quiet them is weakened.
Inflammatory processes in both the brain and peripheral nerves also play a role. Researchers have found elevated levels of certain inflammatory molecules in the blood and spinal fluid of FMS patients, including chemicals that bind directly to pain receptors. Some evidence points to inflammation in the hypothalamus, a brain region involved in stress response, sleep, and hormonal regulation, as an early contributor to the condition.
Symptoms Beyond Widespread Pain
Pain is the hallmark of FMS, but it rarely travels alone. The core symptoms cluster together: chronic widespread pain, fatigue, unrefreshing sleep, cognitive difficulties, and depressed mood. In patient surveys, fatigue and sleep quality often rank as burdensome as the pain itself.
The fatigue in FMS is not ordinary tiredness. It can show up physically as complete exhaustion, emotionally as a loss of motivation, and cognitively as an inability to concentrate. Many people describe a mental fog, sometimes called “fibro fog,” that makes it hard to follow conversations, remember words, or complete routine tasks. This cognitive dysfunction can affect the ability to work, manage household responsibilities, or participate in social activities.
Sleep disturbances are nearly universal. Even after a full night in bed, people with FMS typically wake feeling unrefreshed. Conditions like restless leg syndrome and sleep apnea are more common in this population and can compound the problem. Anxiety and depression frequently co-occur, though researchers view these as part of the same neurological disruption rather than a separate psychological issue.
Conditions That Overlap With FMS
FMS rarely exists in isolation. It frequently overlaps with irritable bowel syndrome (IBS), chronic fatigue syndrome, temporomandibular joint disorders (TMJ), migraines, interstitial cystitis, and restless leg syndrome. People with TMJ who also have fibromyalgia tend to experience more intense and longer-lasting jaw pain than those with TMJ alone. The more overlapping conditions someone has, the higher their overall pain burden tends to be. These overlaps suggest a shared underlying mechanism involving how the central nervous system processes sensory information.
Who Gets FMS
Fibromyalgia affects roughly 2% to 5% of the world’s population. It has long been considered a predominantly female condition, with women making up 80% to 96% of diagnosed cases. However, more recent research suggests the actual gap may be narrower than clinical data implies. A systematic review looking at men and women worldwide found prevalence rates of about 4% in women and 2.4% in men. Men with FMS may be underdiagnosed because their symptoms present differently or because clinicians are less likely to consider fibromyalgia in male patients.
How FMS Is Diagnosed
There is no blood test, imaging scan, or lab result that confirms fibromyalgia. Diagnosis relies entirely on clinical criteria, which is one reason it often takes years to get an accurate answer. The American College of Rheumatology uses two primary scoring tools. The Widespread Pain Index maps pain across 19 body regions, while the Symptom Severity Scale rates fatigue, unrefreshing sleep, and cognitive symptoms on a scale of severity.
A diagnosis requires meeting one of two score combinations: a pain index of 7 or higher with a symptom severity score of 5 or higher, or a pain index between 3 and 6 with a symptom severity score of 9 or higher. In both cases, symptoms must have been present at a similar level for at least three months, and no other condition can better explain the pain.
Because FMS mimics many other diseases, doctors typically run blood work to rule out alternatives. Common tests include complete blood count, thyroid function, C-reactive protein, vitamin D levels, and erythrocyte sedimentation rate. These tests are expected to come back normal in someone with fibromyalgia. The condition is often called a diagnosis of exclusion: doctors systematically rule out thyroid disease, autoimmune conditions, and other causes of pain and fatigue before landing on FMS.
Treatment Approaches
FMS management typically combines medication with lifestyle changes. For years, only three medications carried FDA approval for the condition. In August 2025, the FDA approved a fourth: a low-dose sublingual form of cyclobenzaprine (Tonmya), a muscle relaxant that has been available in higher doses since 1977 for acute muscle spasm. In its new formulation, taken at bedtime, it modestly improved both pain and sleep quality in clinical trials.
Medications for FMS generally target the neurotransmitter imbalances that drive the condition, aiming to boost serotonin and norepinephrine or calm overactive pain signaling. No single drug eliminates symptoms, and most people benefit from a combination of pharmacological and non-pharmacological strategies.
On the non-drug side, cognitive behavioral therapy (CBT) has the strongest evidence base. It’s particularly effective for people who catastrophize, or mentally amplify, their pain experience. Brain imaging studies have shown measurable changes in how the brain processes pain after CBT. Mindfulness meditation also shows promise. Regular aerobic exercise, while difficult to start when you’re in pain, consistently improves symptoms over time. Acupuncture has a weaker evidence base for FMS specifically, though its low risk profile means it remains a reasonable option to try.
The Search for a Biomarker
One of the biggest frustrations with FMS, for patients and clinicians alike, is the absence of an objective test. Recent research has investigated a stress-related protein called GDF15 as a potential blood-based marker. In one study, GDF15 levels were significantly higher in fibromyalgia patients than in healthy controls, and the test picked up 96.7% of true cases. The catch: it also flagged nearly half of healthy people as positive, making it too imprecise to work as a standalone diagnostic tool. Researchers believe that combining GDF15 with other markers, including inflammatory molecules like IL-6 and IL-8, could eventually produce a reliable multi-marker blood panel, but no such test is available in clinical practice yet.